Single-dose intravenous gene therapy injection of onasemnogene abeparvovec-brve for spinal muscular atrophy

This code represents the administration of onasemnogene abeparvovec-xioi, a gene therapy for spinal muscular atrophy (SMA). It involves a single-dose intravenous infusion designed to deliver a functional copy of the SMN1 gene to motor neuron cells. This treatment aims to halt the progression of SMA by enabling the production of the survival motor neuron (SMN) protein.

This code is used for the billing of the onasemnogene abeparvovec-xioi drug itself, not the administration service. It is applicable for patients diagnosed with SMA, typically infants and young children, who meet specific clinical criteria for this gene therapy. Documentation should clearly support the patient's diagnosis of SMA, the medical necessity for this specific gene therapy, and the administration of the drug.